Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06623266

Neck Observation or Elective Neck Dissection in CT1N0M0 OSCC

To evaluate the clinical outcomes of 2-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life in the patients with cT1N0M0 oral squamous cell carcinoma, who receive primary lesion resection combined with elective neck dissection or primary lesion resection only.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Huashan Hospital, Fudan University

Shanghai, 200040, China

Location status: Recruiting

Location contact

Can Xiao, MD, PhD

CONTACT

Can-hua Jiang, MD, PhD

CONTACT

Chao Chen, MD, PhD

CONTACT

Cheng-zhe Yang, MD, PhD

CONTACT

Chuan-yu Hu, MD, PhD

CONTACT

Fa-yu Liu, MD, PhD

CONTACT

Hui-yong Zhu, MD, PhD

CONTACT

Jian Meng, MD, PhD

CONTACT

Jian-bo Xu, MD

CONTACT

Jing-song Li, MD, PhD

CONTACT

Kai Yin, MD

CONTACT

Lai-ping Zhong, MD, PhD

CONTACT

[email protected]

+862152888915

Lei Tao, MD, PhD

CONTACT

Lei Xie, MD, PhD

CONTACT

Li-song Lin, MD, PhD

CONTACT

Liang Gu, MD

CONTACT

[email protected]

+862152889999 ext. 7182

Liang Gu, MD

CONTACT

Tian-shu Xu, MD

CONTACT

Wei-jie Dong, MD

CONTACT

Wen-bo Yang, MD

CONTACT

Xue-kui Liu, MD, PhD

CONTACT

Yan-ming Liu, MD, PhD

CONTACT

Yong-hong Zhang, MD

CONTACT

Yu Wang, MD, PhD

CONTACT

Yu-lin Jia, MD, PhD

CONTACT

Zhi-en Feng, MD, PhD

CONTACT

About this study

For the patients with cT1N0M0 oral squamous cell carcinoma (OSCC), surgical resection of primary lesion is the preferred treatment. However, there are still debates on the neck management, some surgeons suggest elective neck dissection (END), and some surgeons suggest neck observation (NOB). The advantage of elective neck dissection is to clear the potential occult neck lymph node metastasis (about 15%), which could not be detected by clinical examination and imaging examination, and the disadvantage of END is to cause neck deformity, large scars, stiff neck and shoulders, difficulty in raising shoulders, and increase medical costs. The disadvantage of NOB is the risk of lymph node metastasis and disease progression. However, recent retrospective studies show that END has no potential benefit in improving survival in cT1N0M0 patients. The aim of the present trial is to compare the clinical outcomes between the cT1N0M0 OSCC patients, who receive primary lesion resection combined with elective neck dissection or primary lesion resection only, on the aspects of 2-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life. A total number of 300 patients will be recruited, including 150 patients in the experimental arm and 150 patients in the control arm. Experimental arm: radical resection of the primary lesion only, with neck observation, the safety margins of the primary lesion are 1.0-1.5cm far away from the palpable margins of the lesion. Control arm: radical resection of the primary lesion with 1.0-1.5cm safety margins, and elective neck dissection. A complete medical history will be obtained and tumor assessment will be performed at baseline. Patients will be followed-up by every three months in the first 2 years, every six months in the next 3-5 years, and once a year thereafter until death or data censoring. Two-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life will be collected and analyzed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Tumor site: tongue, gingiva, buccal mucosa, floor of mouth, hard palate, retromolar eara
  • Clinical stage is cT1N0M0 (AJCC 8th edition)
  • Pathological diagnosis of squamous cell carcinoma
  • Sign the informed consent form

Exclusion criteria

  • More than 2 lesions found in the oral cavity
  • Known history of malignant tumor within five years (unless the patient has undergone curative treatment and there is no disease recurrence within 5 years since the start of treatment)
  • History of unilateral or bilateral neck dissection in the past
  • History of previous head and neck radiotherapy
  • Pregnant or lactating women
  • Severe, uncontrolled infection or known HIV infection; or previous organ transplantation, stem cell or bone marrow transplantation
  • Participated in other clinical studies within 30 days before enrollment
  • Other circumstances that the researcher considers unsuitable for participation in the study

Treatment and study plan

Neck management

Procedure

In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.

In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.

Primary outcomes

  1. Rate of 2-year lymph node metastasis

    Time frame: 2 years

    Lymph node metastasis is confirmed by pathological examinations, using fine needle aspiration cytology or biopsy. The rate of 2-year lymph node metastasis rate is reported as the percentage of patients who are free from lymph node metastasis for 2 years from the date of randomization.

Secondary outcomes

  1. Rate of 2-year disease free survival

    Time frame: 2 years

    Disease free survival is calculated from the date of randomization to local recurrence, regional recurrence, distant metastasis or death. The rate of 2-year disease free survival is reported as the percentage of patients who are disease free survival for 2 years from the date of randomization.

  2. Rate of 2-year overall survival

    Time frame: 2 years

    Overall survival is calculated from the date of randomization to death. The rate of 2-year overall survival is reported as the percentage of patients who are overall survival for 2 years from the date of randomization.

  3. Health-related quality of life

    Time frame: 2 years

    Health-related quality of life will be measured and scored using the Chinese version of the University of Washington Quality of Life (UW-QOL) scale. Each score ranges from 0 to 100 points. The lower the score, the worse the functional perception.

Study contacts

Contact information is provided by the study sponsor or research team.

Lai-ping Zhong, MD, PhD

CONTACT

[email protected]

+862152888915

Liang Gu, MD

CONTACT

[email protected]

+862152889999 ext. 7182

Sponsors and collaborators

Lead sponsor

Huashan Hospital

Other

Registry information

Official study title

Neck Observation Versus Selective Neck Dissection in Patients with CT1N0M0 Oral Squamous Cell Carcinoma: a Multicenter Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
Oct 2, 2024
Registry last updated
Nov 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.